Study S000623

Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity: A Placebo-Matched Randomised Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06180616
Acronym: TZP-T1D
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 40
Start: 2026-12
Primary completion: 2028-12
Lead sponsor: Royal North Shore Hospital
Conditions: Type 1 Diabetes Mellitus; Overweight and Obesity
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Body weight [32 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016603	Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol. Purcell AR, BMJ open	2025	Protocol	PMID 40962353 DOI	cites ClinicalTrials.gov:NCT06180616; registry reference DERIVED:40962353